Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAN-TU ART: Lecanemab in Dominantly Inherited Alzheimer's Disease
NCT06384573Phase 3Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2024
- Primary completion
- Jun 2030
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of lecanemab in Alzheimer's disease (AD), sponsored by Washington University School of Medicine. Started Jun 2024; status: active, not recruiting.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06384573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06384573.